Clinical trial of Oral Digoxin In NASH (CODIN)
- Study HIC#:2000038275
- Last Updated:10/30/2025
The CODIN Study aims to study the effect of oral digoxin administered once daily (based on titration-based and weight-based dosing) as compared to placebo in resolving fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH; previously NASH). Previous studies have found that digoxin could have protective effects against inflammation in the liver and improve liver health. The study examines a novel approach for the potential management of MASH.
Contact Us
For more information about this study, including how to volunteer, contact:
Suzanne Ford
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion criteria: All must be answered “Yes”
- Male or female, aged 18 to 75 years
- Stable body weight over the last 30 days
- Biopsy-confirmed non-alcoholic steatohepatitis (NASH) on a liver biopsy in the last 6 months (fibrosis stage 2 or 3)
- Willing to have a liver biopsy at baseline (if not performed in the past 6 months) and at the end of treatment
Exclusion Criteria: Please refer to study link on ClinicalTrials.gov
